One of the most extensively researched MCT inhibitors is α-cyano-4-hydroxycinnamic acid (CHC), which has been a hot topic in oncology therapy research and has shown anti-tumor promise in multiple preclinical trials (Duan et al., 2022). This evidence concerns the gene SLC16A1 and neoplasm.